Stivarga Filmtabletten 40Mg(Regorafenib)

Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Stivarga
Manufacturer	Bayer GmbH
Prescription required	Yes

Description

Stivarga Filmtabletten 40Mg(Regorafenib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Regorafenib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Bayer GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Gastrointestinal Stromal Tumors. Pack information: 40 84. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

STIVARGA is a kinase inhibitor indicated for the treatment of adult patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

How to Use

Use Regorafenib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: Regorafenib. Pack size: 40 84. Pack unit: box. Manufacturer: Bayer GmbH. Origin country: Germany. Source category: Medicine Library > Oncology Medicines > Gastrointestinal Stromal Tumors. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

INDICATIONS STIVARGA has not been used to treat children less than 18 years of age. IMPORTANT SAFETY INFORMATION STIVARGA can cause liver problems, which can be serious and sometimes lead to death. Your healthcare provider will do blood tests to check your liver function before you start taking STIVARGA and during your treatment with STIVARGA to check for liver problems. Tell your healthcare provider right away if you experience yellowing of your skin or the white part of your eyes, nausea, vomiting, dark urine, or change in your sleep pattern. Tell your healthcare provider about all the prescription and nonprescription medicines, vitamins, and herbal supplements you take. Avoid drinking grapefruit juice and taking St. John's wort while taking STIVARGA. The most common side effects with STIVARGA include tiredness, weakness, fatigue; diarrhea (frequent or loose bowel movements); loss of appetite; swelling, pain, and redness of the lining in your mouth, throat, stomach, and bowel (mucositis); voice changes or hoarseness; infection; pain in other parts of your body; weight loss; and nausea. Tell your doctor if you have any side effects that bother you or that do not go away. For important risk and use information, please see the full Prescribing Information, including the Boxed Warning.

This information is for reference only. Consult a qualified healthcare professional before using any medicine.